Dynavax’s European Manufacturing Facility Approved for Heplisav

Dynavax Technologies Corporation announced Wednesday that its GMP manufacturing facility in Dusseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of HEPLISAV, the Company’s investigational adult hepatitis B vaccine.
CNNMoney